Mental health medications: market revenue by segment Mexico 2024

Medications for depressive disorders are forecast to account for the largest revenue among mental health medication categories in Mexico in 2024, with a total of 337.6 million U.S. dollars. That year, revenue from anxiety and sleep medications is expected to reach 125.79 million U.S. dollars, while revenue from medications for treating psychotic disorders is estimated at 102.76 million U.S. dollars.

Revenue of the mental health medications market in Mexico in 2024, by segment (in million U.S. dollars)

Characteristic	Revenue in million U.S. dollars
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

More information

Supplementary notes

Data provided by Statista Market Insights are estimates.

Mental health disorders are common illnesses found among people all over the world. These disorders are caused by a variety of genetic and environmental factors that cause imbalances in a person's physical and emotional behavior. Most mental health disorders can be treated with behavioral and psychotherapies. In some cases, however, medication is prescribed along with these treatments. The mental health market represents the market for the drugs that are used to treat various mild to serious mental health disorders. The market is divided into three markets that have been based on the disorders that are being treated. This includes depressive disorders, anxiety and related sleeping disorders, and different types of psychotic disorders.

Market values represent the revenues generated by manufacturers and are based on retail prices for each drug category including all drugs, regardless of whether they are reimbursed or not.

Company examples: Pfizer, Bristol-Myers Squibb, Johnson & Johnson, AbbVie, and Sumitomo pharma

Citation formats